Ligand Pharmaceuticals is one of the new entrants to the pharmaceutical space.
The company has a growing portfolio of drugs that are part of a new generation of biologic therapies that are targeting a particular class of cancer, and it’s looking to cash out to help pay off the debt that it has accumulated since its founding in 2015.
But what’s interesting about Ligands drugs is that its a pharmaceutical company.
The bulk of its revenue is generated from its biologic drug portfolio, which includes therapies for breast, prostate, colon, lung, ovarian, and lung cancer.
Ligando is trying to figure out how to get its drugs into the hands of people with existing cancer treatments.
The two companies are also working together to develop a vaccine for colorectal cancer, which Liganda is developing for use in developing countries.
In a way, Ligande is a spinoff from Timber Pharmaceuticals, a startup that had been developing a new type of drug called Lixx that was marketed to treat patients with advanced cancer.
The LixX vaccine is a big departure for Ligant pharmaceuticals.
The first version of Lixox, for example, had a 10-fold better efficacy rate than Ligandeds Lixo-5, and was also cheaper than Lixax.
Lixxpand has been a hit for LIGanda, but that’s not to say it’s a surefire hit.
LIGAND is still building a drug pipeline, which means it’s also trying to find investors who will fund the company and get it off the ground.
The biggest challenge to getting Ligandi’s drugs into patients’ hands is that it’s got to be approved by the FDA before it can be sold on the generic market.
That’s a huge hurdle for the company.
“The FDA has the authority to approve a drug for a certain class of drugs and we can’t sell it,” Ligandan CEO Robert Krieger told Business Insider in March.
“That means we have to find an investor who will pay for our drugs and make sure they get approved.”
The company is also looking for a partner to help finance the development of the drug pipeline.
Liggand is trying a different approach to getting its drugs to patients than Timber.
It’s partnering with a pharmaceutical firm called Nucleus to create a biologics company that will create generic versions of its drugs for patients with existing treatments.
“Nucleus is a pharma company and Nuclei is a biotech company,” Kriegers told Business Insiders.
“They are both in the biotech space and they’re both in a very aggressive phase of developing products.”
LIGand has not revealed which drugs it will use to develop its generic version of the Lixex, but the company says it has been using Lixxx for years, and the FDA approved the drug for use by more than 100,000 patients in the U.S. So, basically, LIGande is looking to make sure it’s the first drug that gets into the patients hands, even though its not clear how long that will take.
That said, Ligeands new drugs will probably have a much lower price tag than Timber’s Lixux and Lixpand, which are both more expensive and more complicated.